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Abstract
The United States–Affiliated Pacific Islands (USAPI) are part of the US National Tuberculosis 
(TB) Surveillance System and use laboratory services contracted through a cooperative agreement 
with the Centers for Disease Control and Prevention (CDC). In 2004, the CDC established the 
National Tuberculosis Genotyping Service, a system to genotype 1 isolate from each culture-
confirmed case of TB. To describe the molecular epidemiology of TB in the region, we examined 
all Mycobacterium tuberculosis isolates submitted for genotyping from January 1, 2004, to 
December 31, 2008. Over this time period, the USAPI jurisdictions reported 1339 verified TB 
cases to the National Tuberculosis Surveillance System. Among 419 (31%) reported culture-
confirmed TB cases, 352 (84%) had complete genotype results. Routine TB genotyping allowed, 
for the first time, an exploration of the molecular epidemiology of TB in the USAPI.
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Introduction
The United States–Affiliated Pacific Islands (USAPI) include 3 US territories (American 
Samoa, the Commonwealth of the Northern Marianas Islands, and Guam) and 3 independent 
nations (Federated States of Micronesia [FSM], Republic of Marshall Islands [RMI], and 
Palau) associated with the United States through the 1986 US Compact of Free Association.
1
 The compact mandates certain economic provisions, including economic support and 
technical assistance by the US Centers for Disease Control and Prevention (CDC) for the 
tuberculosis (TB) control programs in the 6 USAPI jurisdictions.
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Since 2002, the USAPI have reported each confirmed TB case to the CDC via the National 
Tuberculosis Surveillance System (NTSS).2 TB case rates in the USAPI have been 2- to 50-
fold higher than in the US states with the highest case rates (Hawaii, with a case rate of 
9.2/100 000 population in 2009).2 USAPI jurisdictions face unique challenges with limited 
health care infrastructure, highly mobile populations, varied economic and social conditions, 
and population centers separated by vast expanses of ocean. TB programs in the USAPI 
have struggled to diagnose and manage TB patients according to the World Health 
Organization DOTS Plus strategy.3 For example, radiography services were often 
inaccessible, and diagnosis was based primarily on acid-fast bacilli sputum smear results, 
with the ability to obtain culture not consistently available until 2007. Public health 
programs also lacked human resources to provide treatment of TB disease via directly 
observed therapy.
In 2004, the CDC established the National TB Genotyping Service (NTGS) to genotype at 
least one Mycobacterium tuberculosis isolate from every culture-confirmed TB case 
reported in the United States, including the USAPI.4 USAPI’s initial participation in the 
NTGS was limited due to logistical challenges and the high cost of processing and shipping 
isolates from the USAPI to the United States. In 2007, the CDC established a contractual 
agreement with a regional laboratory in Hawaii to provide shipping, culture in liquid media, 
and drug susceptibility testing for all isolates from the USAPI. While the application of TB 
genotyping has utility in low-burden, high-resource settings,5,6 whether TB genotyping 
could be implemented or could have program-matic relevance in a high-burden, low-
resource setting, such as the USAPI, was unclear.
The molecular epidemiology of TB in the USAPI had not previously been described. In this 
descriptive analysis, we described the implementation and results of TB genotyping in the 
USAPI, including one of its initial applications in the region, when genotyping assisted in 
the investigation of an outbreak.
Methods
The USAPI jurisdictions performed Ziehl-Nielson smear microscopy to make a preliminary 
TB diagnosis and then shipped sputum specimens to the regional laboratory in Hawaii, for 
additional testing by Truant auramine-rhodamine staining followed by fluorescent 
microscopy and liquid media culture.7 For genotyping, primary cultures positive for M 
tuberculosis were subcultured in a liquid medium (10% glycerol in Dubos Davis broth with 
Tween and albumin). Subcultures were incubated at 37°C, with visual monitoring for 
growth.8 On culture growth, isolates were batched and shipped to the NTGS laboratory in 
California for genotyping.
TB genotypes were determined by using a standardized protocol for spacer oligonucleotide 
typing (spoligotyping) and a panel of 12-locus mycobacterial interspersed repetitive unit-
variable number of tandem repeats (MIRU-VNTR).9–11 To facilitate communication of 
genotype data, the national “PCR Type” naming convention was used, where “PCR” is 
followed by 5 digits, which are assigned sequentially to each unique spoligotype and 12-
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locus MIRU-VNTR combination identified in the United States and its affiliated territories.
12
The study population included all verified TB cases reported from January 2004 to 
December 2008. We determined the total number of TB cases reported to the NTSS (ie, with 
surveillance records), the number and proportion of those that were culture-confirmed, and 
the number and proportion of total reported culture-confirmed TB cases with a valid 
genotype. NTGS results were linked to individual NTSS case records using a standardized 
case identification number and a unique laboratory accession number, thus forming discrete 
genotype/surveillance patient-level records in a linked data set.2 These lists are not name 
based or maintained in one location, making the process of linking records challenging. We 
examined linking inconsistencies to determine the proportion of eligible culture-positive TB 
cases with valid genotype results.
When multiple isolates were genotyped for the same individual in the same surveillance 
year, the first genotype result was included in analysis. Two patients with discordant 
genotyping results were excluded from analysis.
A TB genotype cluster was defined as at least 2 cases with matching PCR Types (ie, 
indistinguishable spoligotype and 12-locus MIRU-VNTR results) reported from the same 
USAPI jurisdiction during the study period.
Univariate analyses were used to determine demographic and epidemiologic factors 
associated with genotype clustering. We estimated the relative genetic diversity of isolates 
collected in the USAPI. Methods for assigning phylogenetic lineages and subfamily were 
primarily based on spoligotype and in some instances, 12-locus MIRU-VNTR results, as 
described by Kato-Maeda et al.13
Results
During the 2004 to 2008 study period, 533 M tuberculosis isolates from the 6 USAPI 
jurisdictions were genotyped. Figure 1 shows the number of genotyped isolates within each 
jurisdiction by year. Regionally the number of patients with isolates sent for genotyping has 
increased over the last 5 years from <50 in 2004 to 191 in 2008.
During the same time period, the USAPI jurisdictions reported 1339 verified TB cases to the 
NTSS. Among those the number of reported cases that linked to a genotyped isolate was 352 
(84%; Table 1). There were 2 patients with discordant genotype results and thus were 
excluded from final analysis.
A number of isolates with complete TB genotype results did not correspond to a patient that 
had been reported to NTSS. However, the discrepancies were not unidirectional. As shown 
in Figure 2, the NTGS genotyped 532 nonduplicate isolates and the NTSS reported 419 
culture-confirmed cases. Of the 419, 253 (60%) had genotyping results. There were 180 
isolates with genotyping results that were not successfully linked to a reported TB case. 
There were 14 genotyped isolates that linked to cases that were not reported as culture-
confirmed and 85 where culture data were missing.
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Among the 6 USAPI jurisdictions, FSM and RMI reported the largest number of TB cases. 
These 2 jurisdictions also had a higher proportion of cases that clustered within each 
jurisdiction. In FSM and RMI, 85% of cases were in genotype clusters. Table 2 shows the 
percentage of cases within the genotype clusters by jurisdiction.
In total, 38 TB genotype clusters were identified with 263 (75%) TB cases belonging to a 
cluster. The most prevalent genotype patterns were East-Asian, Beijing (PCR00803 [22%] 
and PCR00002 [8%]), IndoOceanic, Manila (PCR00041 [12%] and PCR00017 [5%]),13,14 
and Euro-American, Latin American Mediterranean (PCR03135 [4%]; Table 3).
Three genotype patterns were predominantly found within 1 USAPI jurisdiction. All 
PCR03135 cases and nearly all PCR00017 (82%) cases were identified in FSM. PCR00803 
and other East-Asian, Beijing genotypes were common among the RMI cases, but 
PCR00803 was rarely seen in the other 5 USAPI jurisdictions.
Discussion
Reliable laboratory diagnosis is one of the cornerstones of TB control. New laboratory 
resources in USAPI, established in 2007, increased confirmed TB diagnoses with culture 
results and TB genotyping. Routine TB genotyping allowed, for the first time, an exploration 
of the molecular epidemiology of TB in the USAPI.
The 6 USAPI jurisdictions increased the number of M tuberculosis isolates submitted for 
genotyping between 2004 and 2008. Certain genotype patterns (eg, PCR00803 in RMI) 
appear to be more prevalent within certain jurisdictions. Genotype clustering has been used 
to estimate disease attributable to recent transmission in other populations, but it is unclear 
whether that can be applied to the USAPI given the predominance of a few highly prevalent 
strains and the low proportion of culture-positive cases among reported cases. These factors 
make it difficult to discern endemic circulating strains from novel strains, which may be a 
result of recent TB transmission events. As the proportion of culture-positive cases with 
subsequent genotyping results increases, the expected prevalence of each genotype will be 
better understood and TB controllers may more readily recognize unusual clustering that 
might be attributable to recent transmission, or potential outbreaks.
This was the first analysis of the molecular epidemiology in the USAPI; however, this study 
does have limitations. First, the implementation of genotyping in the USAPI was dependent 
on consistent support for shipping of specimens to a regional laboratory for culture and 
subsequent testing; therefore, there were limited data from the first 3 years of the study 
period. Second, the surveillance system remained paper-based through 2008, making the 
linking of data between the NTSS and the NTGS difficult and likely leading to missed 
linkages between the 2 data sets. Finally, because genotyping results were not available for 
many TB cases, the degree of clustering and inferences about the proportion of cases 
attributed to recent transmission may be distorted.
Genotyping is an important adjunct to epidemiologic investigations. Contact investigations 
around contagious TB patients are important to identify and treat others who might have 
active TB disease or recent TB infection. However, when contact investigations are 
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incomplete, it can be difficult to ascertain transmission venues and identify persons at 
highest risk of latent TB infection, or progression to active disease. In these situations, 
particularly, genotyping can help a TB program identify additional patients who may be in 
the same chain of transmission.15
The overall utility of genotyping to the region was limited not only by the proportion of 
culture-confirmed cases that have isolates submitted for genotyping but also by the 
proportion of total cases that are culture-confirmed, which was only 31% of reported TB 
cases during the study period. In addition, although the relevance of phylogenetic lineage is 
not fully understood, recent evidence suggests that lineages are associated with clinical 
manifestations and might have implications on diagnosis and treatment.14
The completeness and accuracy of surveillance systems directly affect the utility of 
genotyping to understand the molecular epidemiology of TB in a geographic region. 
Because TB genotyping can only be performed on culture-confirmed cases (ie, with a M 
tuberculosis isolate), our finding in 5 USAPI jurisdictions that the number of genotyped 
isolates exceeded the number of culture-confirmed cases is counterintuitive. This 
discrepancy highlights an important gap in the reporting of TB cases to the NTSS. Recent 
implementation of an electronic reporting system has aided jurisdictions in improving all 
data management activities in USAPI, specifically surveillance efforts in reporting all 
culture-confirmed cases. Finally, CDC’s newly introduced Tuberculosis Genotyping 
Information Management System12 will improve the USAPI’s access to genotyping results, 
more easily linking them to surveillance records, thus shortening the time interval before 
genotyping findings can be applied to routine TB control activities.16
Conclusion
Descriptions of the implementation and utilization of TB genotyping in low-resource 
settings are few in number. Molecular methods when applied universally to all culture-
confirmed isolates can help provide information about chains of transmission, discover 
epidemiologic links that would otherwise be missed, and identify outbreaks. As TB 
surveillance systems in the USAPI improve and more isolates are sent for culture and 
subsequent genotyping, molecular methods will add to the ability of TB control programs to 
understand transmission within and between jurisdictions.
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A Case Study: Application of Genotyping in an Outbreak Investigation in 
the Federated States of Micronesia (FSM)
One of the most common uses of molecular epidemiology is to detect and confirm 
outbreaks.16,17 In July 2008, Chuuk State, FSM, experienced the emergence of 
multidrug-resistant (MDR) TB. FSM requested onsite assistance from CDC to investigate 
these cases.18,19 This outbreak investigation gave context to using TB genotyping data in 
USAPI and prompted the initial examination of the molecular epidemiology of M 
tuberculosis in these jurisdictions.
Molecular epidemiology helped demonstrate 2 distinct outbreaks where there had been 
thought to be only one. Three patients had 5-drug resistant MDR TB, with an East-Asian, 
Beijing genotype (PCR00002: spoligotype: 000000000003771; 12-locus MIRU-VNTR: 
223325173533). The investigation determined that the index patient was likely infected 
with a PCR00002 isolate while working abroad alongside other foreign nationals in 
garment factories. Two other patients with 3-drug resistant MDR TB and a distinct 
genotype (PCR00286; spoligotype: 777777777760771; 12-locus MIRU-VNTR: 
223325143323) both lived in the same village where 22 other cases of TB had been 
diagnosed during the preceding 3 years. Prior to the MDR TB cases, all the culture-
confirmed cases associated with that village had isolates with the same PCR00286 
genotype pattern, a potential 2-drug resistance profile that was a precursor of the MDR 
TB outbreak genotype. The index patient in this second outbreak had a history of TB and 
acquired MDR TB over the course of treatment, likely due to lack of adherence and poor 
directly observed therapy practices.
The genotype in the first outbreak, PCR00002, accounts for approximately 15% of TB 
cases in FSM. The combination of this genotype and drug susceptibility pattern has only 
been seen in patients who acquired TB disease through the chain of transmission initiated 
by the index patient.
The genotype in the second outbreak, PCR00286, had only been seen in patients 
epidemiologically linked to others living in the same village. Transmission of this 
genotype had been documented over the preceding 3 years in this village with both a 2- 
and 3-drug-resistant profile.
The genotyping data proved to be critical in identifying not only 1 outbreak, but 2 
outbreaks that were occurring simultaneously, on the central island of Weno, Chuuk 
State. The subsequent diagnosis and active case-finding activities for both of these 
outbreaks targeted 2 different villages, with slightly different strategies to TB screening 
and treatment of presumed MDR latent TB infection.
Bamrah et al. Page 7
Asia Pac J Public Health. Author manuscript; available in PMC 2020 February 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Number of genotyped isolates in each jurisdiction by year—USAPI, 2004–2008.
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Figure 2. 
Number of surveillance records, culture-confirmed cases, and genotyped isolates, 2004–
2008.
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Table 1.
Number of TB Cases Reported, With Culture Confirmation, and With Genotype Results by Jurisdiction—
USAPI, 2004–2008.
Jurisdiction
No. of TB Cases 
Reported to Surveillance 
System, N
No. of Culture-Confirmed 
Cases in Surveillance Records, 
n (%)a
No. of Isolates 
Submitted to 
Genotyping 
Laboratory, n
No. of Genotyped Cases 
Linked to Surveillance 
Records, n
American Samoa 16 6 (38) 9 8
CNMI 201 64 (32) 93 77
FSM 468 66 (14) 152 98
Guam 350 163 (47) 71 55
Palau 54 11 (20) 25 21
RMI 250 109 (44) 182 93
Total 1339 419 (31) 532 352
Abbreviations: TB, tuberculosis; USAPI, United States–Affiliated Pacific Islands; CNMI, Commonwealth of the Northern Marianas Island; FSM, 
Federated States of Micronesia; RMI, Republic of the Marshall Islands.
apercentages are using the number of surveillance records as the denominator.
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Table 2.
Genotype Clustering by Jurisdiction—USAPI, 2004–2008.
Jurisdiction
Number of Genotype 
Clustersa
Range of Number of Cases Within Each 
Cluster
Percentage of Cases Within a 
Genotype Cluster
American Samoa 1 2 25
CNMI 4 2–19 46
Guam 11 2–15 65
FSM 15 2–19 85
Palau 3 3–4 45
RMI 9 2–56 85
Abbreviations: USAPI, United States–Affiliated Pacific Islands; CNMI, Commonwealth of the Northern Marianas Island; FSM, Federated States of 
Micronesia; RMI, Republic of the Marshall Islands.
aGenotype cluster is at least 2 cases in the same jurisdiction with isolates that have matching spoligotype and 12-locus MIRU-VNTR (ie, PCR 
Type).
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Table 3.
Most Common Genotype Patterns—USAPI, 2004–2008.
PCR Type (Lineage) Spoligotype/12-Locus MIRU-VNTR Number of Cases Median Age in Years (Range)
PCR00803 (East-Asian, Beijing) 000000000003771/222325173533 78 40 (8–73)
PCR00041 (IndoOceanic, Manila) 677777477413771/254326223432 43 50 (25–82)
PCR00002 (East-Asian, Beijing) 000000000003771/223325173533 29 32 (1–73)
PCR00017 (IndoOceanic, Manila) 677777477413771/254326223422 11 25 (0–54)
PCR03135 (Euro-American, Latin American-
Mediterranean)
577777607760771/124326163326 9 21 (10–45)
Abbreviation: USAPI, United States–Affiliated Pacific Islands.
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